Clinical Trial Update: Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a 72-hour infusion of ON 01910.Na in patients with myelodysplastic syndromes or acute myeloid leukemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ON-01910.Na (ON-01910 sodium)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED